Enanta Pharmaceuticals logo
Enanta Pharmaceuticals
ENTA | NASDAQ
Chart Builder DCF Calculator
$10.67
-$0.32 (-2.91%)
At close: Nov 16, 2026, 4:00 PM ET
$10.99
+$0.32 (+3.00%)
After-hours: Nov 16, 2026, 7:34 PM ET

Enanta Pharmaceuticals Company Profile

Company profile explained

Company Profile

Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.

Key Executives

Name Position
Jay R. Luly President, Chief Executive Officer & Director
Matthew Kowalsky Chief Legal Officer & Corporate Secretary
Brendan Luu Chief Business Officer
Harry R. Trout VP of Finance & Interim Principal Financial Officer
Jennifer Viera Executive Director of Investor Relations & Corporate Communications
Kathleen S. Capps Executive Director of Accounting, Controller & Interim Principal Accounting Officer
Nathaniel S. Gardiner Consultant
Scott T. Rottinghaus Chief Medical Officer
Tara Lynn Kieffer Chief Product Strategy Officer
Yat Sun Or Chief Scientific Officer

Latest SEC Filings

Date Type Title
Oct 29, 2026 8-K Current Report
Oct 28, 2026 8-K Current Report
Oct 27, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 12, 2026 10-Q Quarterly Report
Aug 10, 2026 8-K Current Report
Aug 10, 2026 4 Filing
Jul 02, 2026 8-K Current Report
Jul 02, 2026 424B5 Filing
View All SEC Filings ➞
Enanta Pharmaceuticals
Enanta Pharmaceuticals logo
Country United States
IPO Date Mar 21, 2013
Industry Biotechnology
Sector Healthcare
Employees 120
CEO Jay R. Luly

Contact Details

4 Kingsbury Avenue Watertown, Massachusetts 02472 United States

Stock Details

Ticker Symbol ENTA
Exchange NASDAQ
Fiscal Year October - September
Reporting Currency USD
CIK Code 0001177648
CUSIP Number 29251M106
ISIN Number US29251M1062
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.